N-Acetyl-3-chloro-dl-tyrosine | 17350-38-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Acetyl-3-chloro-dl-tyrosine
• 英文别名: N-alpha-acetyl-3-chloro-tyrosine；Nα-acetyl-3-chloro-tyrosine；2-Acetamido-3-(3-chloro-4-hydroxyphenyl)propanoic acid
• CAS: 17350-38-8
• 化学式: C₁₁H₁₂ClNO₄
• 分子量: 257.674
• InChiKey: APDUUXFQFXCZKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-Acetyl-3-chloro-dl-tyrosine 、 1-[(3-Mercapto-1-oxopropyl)amino]-L-proline 、 N,N'-羰基二咪唑 以 N-甲基乙酰胺 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 Nα-([3-(Nα-acetyl-3-chloro-tyrosylthio)-1-oxopropyl]amino)-L-proline
  参考文献：
  名称：

  Orally effective anti-hypertensive agents

  摘要：

  披露了新型硫醇酯化合物，它们是口服有效的血管紧张素转化酶抑制剂，用于治疗哺乳动物的 hypertension。它们具有以下公式，R.sub.1 -A.sub.1 -S-Z，其中 Z 表示 -B-A.sub.2，R.sub.1 是 H 或一个酰基团，A.sub.1 是至少含有一个氨基或亚氨基 -N- 的羧酸，A.sub.2 是至少含有一个氨基或亚氨基 -N- 的羧酸或其低级烷基酯或酰胺，B 是一个 2-4 碳骨架链，通过巯基连接到 S，并包括一个碳酰基或磺酰基团，分别通过羧酰胺或磺酰胺连接到 A.sub.2。优选的是 A.sub.2 包含一个 4-6 成员的 C-N 环或一个由一个 N、一个 S 和 3 个 C 原子组成的 5 成员环。

  公开号：

  US04745124A1

文献信息

• Anti-hypertensive agents
  申请人：University of Miami

  公开号：US04690936A1

  公开（公告）日：1987-09-01

  Novel inhibitors of angiotensin converting enzyme having the general formula R--A--S--Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

  揭示了具有一般公式R--A--S--Z的新型血管紧张素转化酶抑制剂，作为血管紧张素转化酶的强效抑制剂，并且是有用的降压药物。
• Angiotensin converting enzyme inhibitors
  申请人：UNIVERSITY OF MIAMI

  公开号：EP0036713A2

  公开（公告）日：1981-09-30

  Novel inhibitors of angiotensin converting enzyme having the general formula R-A-S-Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

  公开了通式为 R-A-S-Z 的新型血管紧张素转换酶抑制剂，它们是血管紧张素转换酶的强效抑制剂，也是有用的抗高血压药物。
• Classification of the oncofetal fibronection level for the indication of diseases and other conditions
  申请人：ADEZA BIOMEDICAL CORPORATION

  公开号：EP2299275A2

  公开（公告）日：2011-03-23

  A method for classifying the level of oncofetal fibronectin in a sample comprises measuring the amount of an oncofetal fibronectin indicating molecule in a sample; comparing the amount of oncofetal fibronectin indicating molecule in the sample to two or more threshold levels derived from the source of the oncofetal fibronectin and classifying the amount of oncofetal fibronectin indicating molecule in the sample according to the highest threshold level that is less than or equal to amount of the oncofetal fibronectin indicating molecule in the sample. The lower threshold may be 50 ng/ml and the higher threshold may be 150 ng/ml. A kit comprises a fibronectin or oncofetal fibronectin binding partner, a non-specific binder, a solid support containing a non-specific binding surface or a sample collection device; and a system for classifying the subject with respect to multiple thresholds.

  一种对样品中胎盘上纤维连接蛋白水平进行分类的方法，包括测量样品中胎盘上纤维连接蛋白指示分子的量； 将样本中的胎盘上纤维连接蛋白指示分子的量与从胎盘上纤维连接蛋白来源中得出的两个或多个阈值水平进行比较，并根据小于或等于样本中胎盘上纤维连接蛋白指示分子的量的最高阈值水平对样本中的胎盘上纤维连接蛋白指示分子的量进行分类。较低阈值可为 50 纳克/毫升，较高阈值可为 150 纳克/毫升。试剂盒包括纤维连接蛋白或胎盘上纤维连接蛋白结合伴侣、非特异性粘合剂、含有非特异性结合表面的固体支持物或样品收集装置；以及根据多个阈值对受试者进行分类的系统。
• Methods for detecting oncofetal fibronectin
  申请人：Hussa Robert

  公开号：US20060024723A1

  公开（公告）日：2006-02-02

  Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronection for selection of concepti are provided.

  提供了检测样品中胎盘上纤维连接蛋白指示分子的方法和产品。还提供了胎盘上纤维连接蛋白的成像方法。在本文提供的某些方法中，样品经试剂处理和/或与非特异性粘合剂接触。本发明提供了用于检测受试者以确定健康和疾病状态以及评估罹患疾病或病症风险的方法。还提供了通过免疫测定和质谱分析等多种方法检测胎盘上纤维连接蛋白指示分子存在的方法。此外，还提供了检测胎盘上纤维蛋白的方法和产品，用于选择受孕者。
• Oncofetal fibronectin as a marker for pregnancy-related indications
  申请人：Hussa Robert

  公开号：US20060024725A1

  公开（公告）日：2006-02-02

  Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided. Methods and products for detection of oncofetal fibronection for selection of concepti are provided.

  提供了检测样品中胎盘上纤维连接蛋白指示分子的方法和产品。还提供了胎盘上纤维连接蛋白的成像方法。在本文提供的某些方法中，样品经试剂处理和/或与非特异性粘合剂接触。本发明提供了用于检测受试者以确定健康和疾病状态以及评估罹患疾病或病症风险的方法。还提供了通过免疫测定和质谱分析等多种方法检测胎盘上纤维连接蛋白指示分子存在的方法。此外，还提供了检测胎盘上纤维蛋白的方法和产品，用于选择受孕者。